Comparison of the pharmacokinetics of piperacillin and sulbactam during intermittent and continuous intravenous infusion

被引:25
作者
Langgartner, J. [1 ]
Lehn, N.
Glueck, T.
Herzig, H.
Kees, F.
机构
[1] Univ Regensburg, Dept Internal Med 1, DE-93042 Regensburg, Germany
[2] Univ Regensburg, Inst Med Microbiol & Hyg, DE-93042 Regensburg, Germany
[3] Univ Regensburg, Dept Pharmacol, DE-93042 Regensburg, Germany
关键词
piperacillin; sulbactam; high-performance liquid; chromatography; beta-lactam antibiotics; time-dependent antibacterial activity; beta-lactamase inhibitor; pharmacokinetics;
D O I
10.1159/000107725
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The antibacterial effect of piperacillin/sulbactam depends on the time of drug concentration above the minimal inhibitory concentration (MIC). Therefore, continuous infusion (Cl) may be a more rational approach than standard intermittent short-term infusion (SI). The study investigated whether Cl achieves effective drug concentrations comparable with SI. Methods: Seven intensive care unit patients received either piperacillin/sulbactam as 4/1 g intravenous infusion over 15 -20 min every 8 h or as 4/1 g intravenous loading dose (15 -20 min) followed by 8/2 g intravenous Cl per 24 h. After 2 days, regimes were crossed over. Results: Pharmacokinetic parameters (mean +/- SD) for Sl piperacillin/ sulbactam were: (1) peak serum concentration: piperacillin 231 +/- 66 mg/l, sulbactam 53.1 +/- 15.0 mg/l; (2) minimum serum concentration: piperacillin 11.5 +/- 14.8 mg/l, sulbactam 4.2 +/- 3.5 mg/l; (3) clearance: piperacillin 197 +/- 72 ml/ min (C 269 +/- 123 ml/min), sulbactam 167 +/- 61 ml/min (Cl 212 +/- 109 ml/min); (4) half-life: piperacillin 2.4 +/- 1.2 h, sulbactam 3.1 +/- 8 1.6 h. Steady-state concentrations during Cl were 25.5 +/- 14.5 mg/l for piperacillin and 8.0 +/- 3.7 mg/l for sulbactam. Average serum concentrations were comparable in both regimens. Conclusion: A large German survey demonstrated that approximately 89% of Pseudomonas aerugionsa have an MIC <= 16 mg/l and approximately 82% have an MIC <= 8 mg/l. According to this threshold, appropriate anti-bacterial concentrations of piperacillin/sulbactam were achievable with Cl. Cl dosing has the additional advantage that less drug is necessary. Further prospective studies are warranted to compare the clinical efficacy of Cl and Sl regimens in bacterial infections. Copyright (C) 2007 S. Karger AG, Basel.
引用
收藏
页码:370 / 377
页数:8
相关论文
共 34 条
[1]   EFFICACY OF CONTINUOUS VERSUS INTERMITTENT ADMINISTRATION OF PENICILLIN-G IN STREPTOCOCCUS-PNEUMONIAE PNEUMONIA IN NORMAL AND IMMUNODEFICIENT RATS [J].
BAKKERWOUDENBERG, IAJM ;
VANDENBERG, JC ;
FONTIJNE, P ;
MICHEL, MF .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1984, 3 (02) :131-135
[2]  
BATRA VK, 1979, CLIN PHARMACOL THER, V26, P41
[3]   RANDOMIZED STUDY OF CARBENICILLIN PLUS CEFAMANDOLE OR TOBRAMYCIN IN THE TREATMENT OF FEBRILE EPISODES IN CANCER-PATIENTS [J].
BODEY, GP ;
KETCHEL, SJ ;
RODRIGUEZ, V .
AMERICAN JOURNAL OF MEDICINE, 1979, 67 (04) :608-616
[4]   Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion [J].
Buck, C ;
Bertram, N ;
Ackermann, T ;
Sauerbruch, T ;
Derendorf, H ;
Paar, WD .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2005, 25 (01) :62-67
[5]   Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing [J].
Burgess, DS ;
Waldrep, T .
CLINICAL THERAPEUTICS, 2002, 24 (07) :1090-1104
[6]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[7]   Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men [J].
Craig, WA .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :1-10
[8]   CONTINUOUS INFUSION OF BETA-LACTAM ANTIBIOTICS [J].
CRAIG, WA ;
EBERT, SC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (12) :2577-2583
[9]  
CRAIG WA, 1990, SCAND J INFECT DIS S, V74, P63
[10]  
Daniel KP, 1996, PHARMACOTHERAPY, V16, P149